NASDAQ:OCGN - Ocugen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.80
  • Forecasted Upside: -16.96 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.78
▼ -0.37 (-6.02%)
1 month | 3 months | 12 months
Get New Ocugen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$4.80
▼ -16.96% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is $4.80, with a high forecast of $10.00 and a low forecast of $0.70. The average price target represents a -16.96% upside from the last price of $5.78.
Buy
The current consensus among 4 investment analysts is to buy stock in Ocugen.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021Roth CapitalBoost Price TargetBuy$9.00 ➝ $10.00Medium
i
Rating by Z. Jallah at Roth Capital
2/9/2021Chardan CapitalDowngradeBuy ➝ NeutralLow
i
Rating by Keay Nakae at Chardan Capital
2/4/2021HC WainwrightUpgradeNeutral ➝ Buy$4.50Low
i
Rating by S. Ramakanth at HC Wainwright
2/3/2021Roth CapitalBoost Price TargetPositive ➝ Buy$1.00 ➝ $8.00High
i
Rating by Z. Jallah at Roth Capital
2/3/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$1.00 ➝ $4.00Medium
i
Rating by K. Kluska at Cantor Fitzgerald
11/16/2020Roth CapitalInitiated CoverageBuy$1.00Low
i
Rating by Z. Jallah at Roth Capital
11/9/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by S. Ramakanth at HC Wainwright
10/9/2020Cantor FitzgeraldInitiated CoverageOverweight$1.00High
i
Rating by K. Kluska at Cantor Fitzgerald
8/17/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by S. Ramakanth at HC Wainwright
8/16/2020Chardan CapitalReiterated RatingBuy$0.70High
i
Rating by Keay Nakae at Chardan Capital
6/3/2020Chardan CapitalLower Price TargetBuy$2.00 ➝ $0.70Medium
i
Rating by Keay Nakae at Chardan Capital
6/1/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by S. Ramakanth at HC Wainwright
5/17/2020Chardan CapitalReiterated RatingBuy$2.00Low
i
Rating by K. Nakae at Chardan Capital
3/30/2020Chardan CapitalReiterated RatingBuy$2.00High
i
Rating by K. Nakae at Chardan Capital
12/20/2019HC WainwrightInitiated CoverageBuy$1.25High
i
Rating by S. Ramakanth at HC Wainwright
11/27/2019Chardan CapitalInitiated CoverageBuy$2.00High
i
Rating by K. Nakae at Chardan Capital
(Data available from 4/18/2016 forward)
Ocugen logo
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $5.78
$5.51
$5.99

50 Day Range

MA: $8.19
$6.15
$10.95

52 Week Range

Now: $5.78
$0.17
$18.77

Volume

17,410,051 shs

Average Volume

56,713,234 shs

Market Capitalization

$1.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocugen?

The following Wall Street analysts have issued research reports on Ocugen in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for OCGN.

What is the current price target for Ocugen?

4 Wall Street analysts have set twelve-month price targets for Ocugen in the last year. Their average twelve-month price target is $4.80, suggesting a possible downside of 17.0%. Roth Capital has the highest price target set, predicting OCGN will reach $10.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $0.70 for Ocugen in the next year.
View the latest price targets for OCGN.

What is the current consensus analyst rating for Ocugen?

Ocugen currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCGN will outperform the market and that investors should add to their positions of Ocugen.
View the latest ratings for OCGN.

What other companies compete with Ocugen?

How do I contact Ocugen's investor relations team?

Ocugen's physical mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company's listed phone number is 484-328-4701 and its investor relations email address is [email protected] The official website for Ocugen is ocugen.com.